Diabetes Control and Complications Trial/epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions

Overview

Journal Diabetes

Specialty Endocrinology

Date 2013 Nov 23

PMID 24264395

Citations 112

Authors

David M Nathan

Margaret Bayless

Patricia Cleary

Saul Genuth

Rose Gubitosi-Klug

John M Lachin

Gayle Lorenzi

Bernard Zinman

Affiliations

Soon will be listed here.

Citing Articles

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S59-S85.

PMID: 39651988 PMC: 11635044. DOI: 10.2337/dc25-S004.

12-Month Time in Tight Range Improvement with Advanced Hybrid-Closed Loop System in Adults with Type 1 Diabetes.

Nigi L, Simon Batzibal M, Cataldo D, Dotta F Diabetes Ther. 2024; 15(12):2557-2568.

PMID: 39347899 PMC: 11561210. DOI: 10.1007/s13300-024-01656-w.

Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial.

Nathan D, Herman W, Larkin M, Krause-Steinrauf H, Abou Assi H, Ahmann A Diabetes Care. 2024; 47(12):2155-2163.

PMID: 39312277 PMC: 11655407. DOI: 10.2337/dc24-1362.

Culturally adapted mobile application for optimizing metabolic control in type 1 diabetes: a pilot study.

Cepeda-Marte J, Moore A, Ruiz-Matuk C, Salado-Diaz D, Socias-Pappaterra P, Ho-Sang V Rev Panam Salud Publica. 2024; 48:e86.

PMID: 39286660 PMC: 11404233. DOI: 10.26633/RPSP.2024.86.

Heterogeneous response of estimated insulin sensitivity indices to metformin in young individuals with type 1 diabetes and different phenotypes.

Ramaldes L, Dos Santos S, Dualib P, de Sa J, Dib S Diabetol Metab Syndr. 2024; 16(1):214.

PMID: 39218890 PMC: 11367792. DOI: 10.1186/s13098-024-01451-4.

References

. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997; 46(2):271-86. View

Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H . Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes. 2007; 56(8):2161-8. DOI: 10.2337/db07-0376. View

. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Diabetes. 1999; 48(2):383-90. PMC: 2622732. DOI: 10.2337/diabetes.48.2.383. View

Boright A, Paterson A, Mirea L, Bull S, Mowjoodi A, Scherer S . Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes. 2005; 54(4):1238-44. PMC: 1621110. DOI: 10.2337/diabetes.54.4.1238. View

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

Ahern J, Grove N, Strand T, Wesche J, Seibert C, Brenneman A . The impact of the Trial Coordinator in the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes Educ. 1993; 19(6):509-12. DOI: 10.1177/014572179301900606. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):786-806. View

Pop-Busui R, Herman W, Feldman E, Low P, Martin C, Cleary P . DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010; 10(4):276-82. PMC: 3608672. DOI: 10.1007/s11892-010-0120-8. View

10.

. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986; 35(5):530-45. View

11.

. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995; 75(14):894-903. DOI: 10.1016/s0002-9149(99)80683-3. View

12.

Downie E, Craig M, Hing S, Cusumano J, Chan A, Donaghue K . Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care. 2011; 34(11):2368-73. PMC: 3198305. DOI: 10.2337/dc11-0102. View

13.

Gerstl E, Rabl W, Rosenbauer J, Grobe H, Hofer S, Krause U . Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr. 2007; 167(4):447-53. DOI: 10.1007/s00431-007-0586-9. View

14.

. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group. Clin Chem. 1987; 33(12):2267-71. View

15.

. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1995; 122(8):561-8. DOI: 10.7326/0003-4819-122-8-199504150-00001. View

16.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

17.

Little R, Rohlfing C, Sacks D . Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem. 2010; 57(2):205-14. DOI: 10.1373/clinchem.2010.148841. View

18.

. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care. 1996; 19(3):195-203. DOI: 10.2337/diacare.19.3.195. View

19.

Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N . Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003; 26(4):1258-64. DOI: 10.2337/diacare.26.4.1258. View

20.

. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology. 1995; 102(4):647-61. DOI: 10.1016/s0161-6420(95)30973-6. View